On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

FAH

fumarylacetoacetate hydrolase

The FAH gene provides instructions for making the fumarylacetoacetate hydrolase enzyme, which is crucial for the final step in the body's breakdown of the amino acid tyrosine. The FAH gene encodes an enzyme called fumarylacetoacetate hydrolase, primarily active in the liver and kidneys.

Chromosome 15q25.1 Autosomal recessive HGNC:3579 Tier C
FAH 15q25.1 p arm q arm 15

FAH is located on the long (q) arm of chromosome 15, at band 15q25.1. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 15 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The FAH gene, or fumarylacetoacetate hydrolase, is fundamental to human metabolism. It directs the production of an enzyme essential for breaking down tyrosine, a common amino acid.

Disruptions to the FAH gene's function can lead to metabolic imbalances, notably Hereditary Tyrosinaemia Type I, which affects key organs like the liver and kidneys. Understanding this gene is important for carrier screening and diagnosing inherited metabolic conditions.

What the gene does

The FAH gene codes for the enzyme fumarylacetoacetate hydrolase. This enzyme functions as the fifth and final step in the metabolic pathway that breaks down the amino acid tyrosine. Specifically, it converts fumarylacetoacetate, a byproduct of tyrosine metabolism, into smaller molecules.

These smaller molecules are then either excreted from the body via the kidneys or utilised for energy production and the synthesis of other substances. The enzyme is most abundant in the liver and kidneys, with smaller quantities found throughout other tissues. Impaired function of this enzyme leads to the accumulation of toxic intermediates, causing cellular damage.

Video: Genetics 101

Chromosome location

The FAH gene is located on chromosome 15, specifically at position 15q25.1. This precise genomic address helps in identifying and studying the gene within the human genome.

Protein structure

The FAH gene produces a protein consisting of 419 amino acids. Domain architecture has not been experimentally characterised in detail for this protein.

Key variants

Variants within the FAH gene can alter the structure and function of the fumarylacetoacetate hydrolase enzyme. These genetic changes can range from single nucleotide alterations to larger deletions or insertions, impacting the enzyme's efficiency or stability. Over 86 distinct variants in the FAH gene have been identified as causes of associated conditions, leading to reduced or absent enzyme activity.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for FAH.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.1014del
Deletion
p.Gly337_Cys338insTer Pathogenic ★★☆☆ Tyrosinemia type I
c.1203C>G
single nucleotide variant
p.Tyr401Ter Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I
c.34T>C
single nucleotide variant
p.Phe12Leu Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I
c.577T>C
single nucleotide variant
p.Cys193Arg Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I
c.608del
Deletion
p.Ala203fs Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I
c.701G>A
single nucleotide variant
p.Trp234Ter Pathogenic/Likely pathogenic ★★☆☆ FAH-related disorder
c.72_81dup
Duplication
p.Pro28fs Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I
c.745C>A
single nucleotide variant
p.Pro249Thr Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I
c.82-1G>C
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I
c.879C>A
single nucleotide variant
p.Tyr293Ter Pathogenic/Likely pathogenic ★★☆☆ Tyrosinemia type I

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in the FAH gene are primarily associated with Hereditary Tyrosinaemia Type I, an autosomal recessive metabolic disorder. This condition is characterised by severe liver and kidney disease, alongside neurological problems. Symptoms typically manifest in infancy due to the accumulation of toxic byproducts from impaired tyrosine metabolism.

Inheritance pattern

Conditions caused by pathogenic FAH variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous FAH carrier status across ancestry groups?

UK clinical status

The FAH gene is listed on several NHS Genomic Medicine Service national panels, indicating its clinical significance within the UK healthcare system. It is included in panels for Cholestasis, Foetal anomalies, Hereditary neuropathy, Hereditary neuropathy or pain disorder, Hypophosphataemia or rickets, Likely inborn error of metabolism, Neonatal cholestasis, Renal tubulopathies, and Undiagnosed metabolic disorders. This demonstrates its relevance in diagnosing a range of inherited conditions.

Frequently asked questions

What is the main function of the FAH gene?

The FAH gene provides instructions for creating the enzyme fumarylacetoacetate hydrolase, which plays a critical role in the final step of breaking down the amino acid tyrosine in the body.

Which condition is primarily associated with FAH gene variants?

Variants in the FAH gene are primarily linked to Hereditary Tyrosinaemia Type I, a severe inherited metabolic disorder affecting the liver, kidneys, and nervous system.

Where is the FAH gene located in the human genome?

The FAH gene is found on chromosome 15, specifically at the band position 15q25.1.

References

  1. Pérez-Carro R, Sánchez-Alcudia R, Pérez B. Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I. Clinical genetics. 2014. PMID: 23895425
  2. Fernández-Lainez C, Ibarra-González I, Belmont-Martínez L. Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico. Annals of hepatology. 2014. PMID: 24552869
  3. Demers SI, Russo P, Lettre F. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia. Human pathology. 2003. PMID: 14691918
  4. Arranz JA, Piñol F, Kozak L. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Human mutation. 2002. PMID: 12203990
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 18 October 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .